Gemzar Lyophilisate For Solution For Injection 1G Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Gemzar: Lyophilisate for solution for injection (1g)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

GEMCITABINE (jem SIT a been) is a chemotherapy drug. This medicine is used to treat many types of cancer like breast cancer, lung cancer, pancreatic cancer, and ovarian cancer.

In-Depth Information

Gemzar 1g Powder for Injection

NDC: 000027502
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Breast Cancer, Pancreatic Cancer, Ovarian Cancer

Sometimes used for but not FDA approved for the following conditions:
Mycosis Fungoides, Biliary Tract Cancer, Mesothelioma, Non-small Cell Lung Cancer (NSCLC), Cutaneous T-cell Lymphoma (CTCL), Bladder Cancer

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Gemzar 1g Powder for Injection

Reported Side Effects for Gemzar 1g Powder for Injection

Blood In The Urine Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Infection Incidence:
<5.0%*
Severity: SEVERE
Onset: DELAYED
Blood Vessel Fluid Leak Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Low Kidney Function Incidence:
<16.0%*
Severity: SEVERE
Onset: DELAYED
Breathing Difficulties Incidence:
<2.0%*
Severity: SEVERE
Onset: RAPID
Elevated Hepatic Enzymes Incidence:
<10.0%*
Severity: SEVERE
Onset: DELAYED
Low Lymphocytes Incidence:
<43.0%*
Severity: SEVERE
Onset: DELAYED
Paresthesias Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Skin Rash Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Hair Loss Incidence:
<18.0%*
Severity: SEVERE
Onset: DELAYED
Decreased Appetite Incidence:
<17.0%*
Severity: MILD
Onset: DELAYED
Constipation Incidence:
<7.0%*
Severity: SEVERE
Onset: DELAYED
Drowsiness Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Shortness Of Breath Incidence:
<4.0%*
Severity: SEVERE
Onset: EARLY
Swelling Incidence:
<13.0%*
Severity: MODERATE
Onset: DELAYED
Tired Incidence:
<7.0%*
Severity: SEVERE
Onset: EARLY
Fever Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Headache Incidence:
<14.0%*
Severity: MILD
Onset: EARLY
High Bilirubin Level Incidence:
<3.0%*
Severity: SEVERE
Onset: DELAYED
Mouth Ulcers Incidence:
<4.0%*
Severity: SEVERE
Onset: DELAYED
Protein In The Urine Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Sore Throat Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Low Blood Pressure Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Bleeding Incidence:
<3.0%*
Severity: SEVERE
Onset: EARLY
Hemolytic-uremic Syndrome Incidence:
0.3%*
Severity: SEVERE
Onset: DELAYED
Upset Stomach Incidence:
1.0-39.0%*
Severity: SEVERE
Onset: EARLY
Loose Stools Incidence:
1.0-4.0%*
Severity: SEVERE
Onset: EARLY
Vomiting Incidence:
2.0-39.0%*
Severity: SEVERE
Onset: EARLY
Low Calcium Levels Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Injection Site Reaction Incidence:
4.0%*
Severity: MILD
Onset: RAPID
Increased Blood Sugar Incidence:
4.0%*
Severity: SEVERE
Onset: DELAYED
Low Platelet Count Incidence:
5.0-55.0%*
Severity: SEVERE
Onset: DELAYED
Anemia Incidence:
7.0-28.0%*
Severity: SEVERE
Onset: DELAYED
Low Magnesium Levels Incidence:
7.0%*
Severity: SEVERE
Onset: DELAYED
Feeling Sick Incidence:
19.0%*
Severity: MILD
Onset: EARLY
Fluid Retention Incidence:
20.0%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cells Incidence:
25.0-71.0%*
Severity: SEVERE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Gemzar

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5